ASX ANNNOUNCEMENT **27 April 2021**

CardieX March 2021 Quarter CEO Update

Highlights

- **Strong sales growth in FY21 continues with YTD sales up over 30% on a constant currency basis (excluding royalties) on the comparative period in FY20**
- **Target sales growth for FY21 revised up to 40% on a constant currency basis - key new team members and market growth driving increased sales targets**
- **Payer reimbursement strategy update**
- **Detailed New product launch update - Mobvoi, Pulse, Arty Band, Digital App and SaaS Platform**
- **Regulatory approvals update and schedule - FDA clearance, CE approval in Europe, and NMPA approval in China**
- **Appointment of Shanty as new brand and marketing "Agency of Record"**
- **Restructured and streamlined manufacturing process delivering significant cost efficiencies**
- **Total cash reserves of $4.8 million at 31 March 2021, following SPP capital raising**

On behalf of CardieX Limited (CardieX, the "Company"), I am pleased to provide the following update on our activities during the March 2021 quarter.

Strong Sales Growth in Traditional Medical Markets

During the quarter, the Company continued to experience strong sales growth which has led to a total increase of over 30% on a constant currency basis (excluding royalties) for the year-to-date (YTD) on the comparative period in FY20.

Strong underlying market demand for our traditional products has resulted in an expanded order book and, when combined with key new appointments to the ATCOR sales team, has led the Company to increase the sales growth target for FY21 up to 40% on a constant currency basis over the previous corresponding period (excluding royalties).

Sales of the XCEL and Oscar 2 devices continue to perform very well in research, clinical trial, Pharma, and specialist clinician markets. We now have five global trials we are supporting with the likes of AstraZeneca and Bayer, as well as being the preferred device supplier for the world's largest study on hypertension and COVID-19 - the CARTESIAN Study - which aims to explore the immediate and long-term vascular consequences of COVID-19.

Other current trials that we support target renal disease, heart failure, and diabetic retinopathy. Our expectation, based on our current sales pipeline, is that we will add one new clinical trial before financial year end.

Based on the strong growth we are seeing in all market segments and with the addition of new devices, our internal sales target for FY22 is for a significant increase over our anticipated results for FY21, which will also result in a return to profitability for the Company by 2022 calendar year-end.

Supporting this growth is the recent addition of Michael Schulz to our ATCOR sales team last month. Michael was previously with Mortara and Welch Allyn (one of the world's largest vital signs monitoring companies owned by Hillrom (NYSE: HRC) US$8B mkt cap) and while at Mortara, Michael was responsible for the growth of the pharmaceutical and cardiology device sales division from $100K to US$65M under his leadership.

Payer Reimbursement Strategy Update.

With the recently announced appointment of Dr. Steven Kesten as our Chief Medical Officer we are aggressively expanding our marketing and advocacy programs with the insurance payers, Medicare and Medicaid, and physician representative groups. Supporting Steven's efforts is Rhonda Welch, who previously managed reimbursement for Johnson & Johnson.

Traditionally, we have focused our sales and marketing efforts on hypertension and related vascular disorders, the largest market opportunity for our vital signs monitoring devices. This has been principally driven by the regulatory, reimbursement, and policy support for the use of our central blood pressure devices in physician practices for hypertension.

Going forward we are expanding our advocacy and reimbursement coverage strategy to target significant new physician sales markets in:

1. gestational hypertension;
2. renal disease;
3. cognitive health; and
4. heart failure.

All the above are new market segments that benefit from the diagnostic application of our devices and solutions.

Expect ongoing announcements on these efforts throughout the year. Our initial focus is on the renal and dialysis market with a formal presentation to the Renal Physicians Association by our medical and scientific team next week. Our end-game is to gather enough support from representative physician groups to provide the foundation for expanded reimbursement coverage for our devices in multiple new health market segments.

While these activities may seem administrative in nature to shareholders who are not familiar with the US healthcare market, these efforts have the potential to exponentially impact our sales and revenues in our medical device business while also providing further validation and support for our consumer device strategy.

New Product Update

We currently have three (3) new devices in various stages of development and production:

1. Our smartwatch collaboration with Mobvoi;
2. Our new consumer vital signs monitor - code named "Pulse" - a "world first" **dual** blood pressure monitor incorporating our patented central blood pressure technology and multiple new, patent-pending, heart-health parameters; and
3. Our new wearable device code named "Arty Band".

We also have multiple ongoing partnership discussions for the licensing of our SphygmoCor® technology for additional new medical devices that do not compete with our current products or licensing agreements with other parties.

Separately we have two (2) digital platforms and solutions in fast-track development which align with our device development timetable:

1. the ArtyGo app - a consumer companion app for our Pulse device incorporating health coaching, remote patient monitoring, and our patented heart-health parameters; and
2. ArtyNet - our physician portal and companion SaaS solution that, paired with the Pulse, provides physicians the ability to directly monitor and care for patients remotely - and directly integrates our devices within the physicians billing and patient management systems.

Mobvoi Project ("MVP")

The upcoming Mobvoi smartwatch incorporates our 100% subsidiary company, ATCOR's Arty™ heart health algorithms utilizing the Company's world-first patent-pending sensor technology (see ASX release: 24 September 2020).

Initial market launch will be in United States, Australia and New Zealand with subsequent global launch in additional markets subject to certain conditions to be agreed by both parties.

Both companies originally planned for a Q3/FY21 launch (March, 2021) to strongly leverage the marketing opportunity of the annual Consumer Electronics Show (CES). Ultimately it was decided that the virtualized CES was not the appropriate commercial launch envisioned to impactfully introduce the smartwatch and Arty to the consumer market.

We have therefore developed alternative go-to-market strategies and we have taken the opportunity to further refine our customized algorithms for sensor integration. All internal development of our Arty™ algorithms and digital platform for the smartwatch has been completed and delivered to Mobvoi for integration into the Mobvoi app platform.

Mobvoi and ATCOR are currently developing a joint pre-market, go-to-market, and general marketing strategy in conjunction with our new Agency of Record ("AOR" see below).

The current development, completion, regulatory, and go-to-market status of MVP is as follows:

1. MVP development work to be complete by Q4/FY21;
2. Pre-launch marketing including KOL reviews begin Q4/FY21;

3. Factory shipment of the first batch of products to occur late Q4/FY21;

4. The MVP launch in the US and Australia/NZ for the initial limited market release will take place early Q1/FY22. The goal of this strategy is to launch to target Amazon Prime Day shoppers; and

5. MVP launch for the full market release will take place early Q3/FY22. This release will take place in the US, Australia/New Zealand, as well as additional global markets (with focus on the European and China market).

No FDA clearance is required for the MVP as it is not being marketed as a medical device.

Pulse

"Pulse" is a new home-based heart health vital signs monitoring system based on ATCOR's FDA-cleared SphygmoCor® technology.

SphygmoCor® is the only existing FDA-cleared technology that can produce a full feature central arterial waveform in adults that identifies advanced cardiovascular diagnostics for heart and other vascular disorders.

Over the last 2-years the Company has been working on refining its SphygmoCor® technology and arterial waveform analysis into a set of consumer parameters that can be incorporated into a consumer priced device targeted at home users as well as primary care physicians.

Pulse is expected to be the **world's first** "dual blood pressure" monitor available for consumers looking to access clinician-grade diagnostics for their health management.

Importantly, Pulse will deliver nine (9) unique, proprietary, and trademarked health parameters that have been developed by the Company for incorporation into the device and which give consumers (and clinicians) significantly more advanced insights into a patient's health and wellness.

Pulse will be priced at a level commensurate with current higher-end consumer blood pressure devices.

CardieX expects Pulse to be a disruptive and industry changing entrant into the global vital signs monitoring market with algorithms that target not just heart health and hypertension, but also provide diagnostic parameters for managing renal disease, arterial health, and cognitive health - all significant new market and revenue opportunities for the Company.

The current development, completion, regulatory, and go-to-market status of Pulse is as follows:

1. The clinical validation study of our patented Central Blood Pressure parameters in the Pulse device is targeted to be completed by Q4/FY21;

2. Additional hardware/device testing of the Pulse device in combination with the ArtyGo App to be completed late Q4/FY21;

3. FDA, CE Mark, & NMPA (China) regulatory submission anticipated to be filed Q1/FY22 (along with ArtyGo App);

4. CE Mark approval anticipated to be received Q2/FY22 while FDA and NMPA approval anticipated to be received late Q2/FY22;

5. Trial Production will begin in Q1/FY22, and mass production (up to 50,000 units) will take place the coming months thereafter in Q2/FY22;
6. The ATCOR Pulse & ArtyGo app pre-launch marketing campaign will begin Q2/FY22; and
7. The product launch of the ATCOR Pulse device anticipated for late Q2/FY22.

New Wearable - Code Name: "Arty Band"

Arty Band is the next evolution of our device strategy with a consumer wearable that provides advanced health diagnostics to consumers including: "cuffless" blood pressure monitoring, our Arty™ health parameters and clinically relevant health parameters that can be used and interpreted by physicians.

Our target market is the 1.3 billion global hypertensives, but also patients with Alzheimer's risk and cognitive decline, as well as those that want health parameters that they can actively use to manage their overall health and particular condition.

Importantly, unlike the Apple Watch and other wearables, **we are targeting FDA clearance on Arty Band's health features** - which we believe will significantly contribute to its market positioning and value and will be a key sales proposition for the clinical/physician markets looking to recommend a remote wearable solution to their patients.

Additionally, our clinical trial partners have been asking us for a wearable solution to support their trials for heart failure and other disorders. Currently they are using non-FDA cleared devices and are looking for more clinically validated/FDA-cleared devices for this purpose, which we will be providing as part of a complete "clinical trial ecosystem of products and solutions".

This will be the first full roll-out of all our Arty™ features and health parameters on a wearable device (Mobvoi has a limited subset of these features for the launch of the watch).

We will be launching multiple new health parameters into the market that are proprietary to our wearable device. One example is a new parameter called eCap™ or "exercise capacity", a new health parameter that gives a user information about his/her heart's ability to perform under stress when exercising. Similar to "VO2 Max" which measures oxygen utilization during exercise this parameter has particular application for general health as well as professional sports given the incidence of heart failure across college and professional sports.

This is just one example of how we are reimagining health metrics for consumers with our devices. Another is our "Vitals Index™" - an essential indicator of the pulse pressure at the brain, which provides patients struggling with cognitive decline an indication of the vascular health of the arteries that impact the brain. Full feature sets and health parameters will be announced when we debut the Arty Band (and Pulse) over the coming months.

In the US we are seeing "unicorn" valuation status reached by wearable companies such as Oura (sleep), WHOOP (exercise performance), and both Levels and Supersapiens (metabolic health). While also having the same general health parameters as general wearable devices, our focus with Arty Band is on owning the **vascular health wearable segment** based on our 25-year history in advanced vascular and heart health algorithms. This is a market segment we are well placed to own and claim given our proprietary, patented, and trademarked health parameters.

Current status is as follows:

1. Design completed and initial (non-working) mock-ups of Arty Band sensor module and straps were delivered this week to USA office;
2. Branding strategy being undertaken by our brand strategy agency - due for completion end-April. Brand strategy and product name announced at that time to the market;
3. PPG sensor partner/provider being contracted;
4. Technology partnerships in contract negotiation for other general health algorithms; and
5. Contract manufacturer being finalized.

The above points, 2-5 are to be finalized in the next 6 weeks.

In addition:

1. FDA clearance to be sought Q2/FY22 (at which time we will release product details and specifications to the market);
2. Pre-marketing and pre-orders to commence Q2/FY22;
3. Mass production to commence Q3/FY22; and
4. Planned release late Q3/FY22/early Q4/FY22 conservatively assuming 6-month FDA submission and clearance turnaround.

Digital Solutions Update

Commensurate with the above device development program we are running a parallel process of development of both ArtyGo, our companion consumer app for Pulse, and ArtyNet - our SaaS solution for physicians as described above.

ArtyGo, to remind shareholders, will be a full featured consumer app paired to Pulse that will provide a digital dashboard for all your health parameters, as well as health tips, notifications, live health coaching, and the ability to remotely share your health readings with your physician. The ArtyGo app will have both a free and subscription component.

The current development, completion, regulatory, and go-to-market status of ArtyGo App is as follows:

1. Development/testing of the ArtyGo app for FDA submission will be completed late Q4/FY21 to early Q1/FY22;
2. Thereafter, development/testing of the ArtyGo app will continue until late Q2/FY22. This will be the version (called MVP version) with enhanced features that will be launched into the market on both iOS and Android;
3. FDA, CE Mark, & NMPA (China) regulatory submission anticipated to be filed Q1/FY22 (along with the ATCOR Pulse device);
4. CE Mark, FDA, and NMPA approval anticipated to be received late Q2/FY22;
5. The ArtyGo app pre-launch marketing campaign will begin Q2/FY22. App store submission

of product will take place late Q2/FY22; and

6. The product launch of the ArtyGo application (along with ATCOR Pulse device) anticipated for late Q2/FY22.

ArtyNet is the physician software platform that allows integration of all of the patient's health readings obtained by our devices into the physicians billing systems and EMR management platform - the software that the physician uses to manage all patient records.

Integrating our devices into the EMR enables a physician to access a patient's vital signs and to obtain reimbursement for remote monitoring of a patient's blood pressure and other health parameters using one of our devices. ArtyNet is a SaaS based platform with pricing TBD.

The current development, completion, regulatory, and go-to-market status of ArtyNet physician portal is as follows:

1. Development/testing of the ArtyNet Portal for FDA submission will be completed by late Q2/FY22. Development work includes cloud backend, Portal UI/UX, CPT reimbursement reporting, EMR integration, & billing integration;
2. FDA regulatory submission anticipated to be filed late Q2/FY22 early Q3/FY22;
3. FDA approval anticipated to be received Q4/FY22;
4. The ARTYNet Portal pre-launch marketing campaign will begin late Q3/FY22; and
5. The product launch of the ArtyNet Portal anticipated for Q4/FY22.

On completion, our Arty Band wearable will also integrate with ArtyGo as the companion app for that device and will also be able to be paired with ArtyNet so that physicians can monitor patient's activities outside of the fixed home environment.

New Product Regulatory Approval Update: FDA (USA), CE Mark (Europe), NMPA (China)

Details on planned project release dates and regulatory schedules are provided in the specific project sections above.

No FDA clearance is required for the Company's first wearable product launch in partnership with Mobvoi (the MVP).

Arty Band will require FDA clearance as we are seeking to have it classified as a "medical device" unlike other consumer wearables that are marketed "for wellness purposes" only (such as the Apple Watch) and thereby avoid having the rigorous scientific testing and validation required for FDA clearance.

It is important to point out that we see little technology risk or validation hurdles for our FDA applications as we move forward with this process.

Our existing SphygmoCor® XCEL device is already the "predicate" testing device used by the FDA in assessing central blood pressure ("cBP"). In effect our new Pulse device will be tested for accuracy (conducted by the FDA or agents on its behalf) of cBP against our **own** existing device, additionally, the brachial blood pressure ("BBP") validation of Pulse will be based on our OEM manufacturers (Andon) existing FDA approved BBP device.

Appointment of Shanty as New Marketing and Brand Agency of Record

As stated above, after undertaking an extensive RFP (Request for Proposal) process from 7 leading brand and strategy agencies we selected Shanty to be our Agency of Record ("AOR") responsible for brand strategy, product marketing, social & influencer marketing, and online/digital go-to-market strategy for all of our new devices.

As part of the brief, Shanty will be helping guide our re-branding of our consumer wellness business to be more representative of our goals and ambitions as a company, with a specific focus on creating brands for our devices that emotionally resonate with our customers.

Like Shanty's other clients, Netflix, Sonos, Twitter, Adidas, Nike, Vans, Kendall&Kylie, we are looking to Shanty to help reposition our brand strategy to represent a next generation health company providing our community with devices and solutions that help them thrive forward in life.

Ultimately what we will end up with under the CardieX holding company will be two separate, but intertwined operating divisions, ATCOR will continue our traditional business of medical devices - a brand vested in the history of its technology and 25 years of advanced cardiovascular solutions for the medical and clinical market.

Separately, our wearable and consumer strategy will be incorporated under a **new consumer focused brand** that we will unveil when the brand strategy exercise is complete - in late April/early May. I am personally very excited about this evolution of the Company and look forward to presenting it to shareholders when completed.

Restructured and Streamlined Manufacturing Process

During the quarter, the company completed the outsourcing of its manufacturing to a new Sydney based manufacturing group - delivering significant efficiencies, both in expenses and logistics. Commensurate with this move the Company also closed its West Ryde facility.

This new outsourcing has resulted in a change to the timing of component material purchasing and cash payments in the current quarter due to the increased sales from our ATCOR division.

Corporate

At 31 March 2021, the Company had a cash balance of $4.8m. This was driven by the oversubscribed SPP that raised $3.15m after costs, customer receipts, staff and development expenses, and increased manufacturing costs due to the timing of inventory and manufacturing purchases mentioned above.

Looking ahead, we continue to be well funded to pursue our growth initiatives in both the existing ATCOR business and the CardieX new device strategy under our soon to be announced consumer brand. In addition, CardieX's listed options (5 cents exercise price and November 2021 expiry) have the potential to raise a further $6.35m if fully exercised.

Payments to related parties and their associates in the quarter were $287k and all related to remuneration for services under existing services agreements, with no non-remuneration payments made in the quarter to those parties.

Final Comments

Finally, I want to thank shareholders for their continuing support. Launching new products is never linear, and there are always challenges along the way that face all technology growth companies.

Having said that I can assure you that we are all working hard on maintaining project schedules and launch targets for all our new products and devices. Certain factors have impacted product launch schedules which are detailed above - and have been further impacted by lack of travel to China and initial delays in obtaining sample and test units due to COVID-19.

I know you will share my mission and vision of making sure that all our new products not only provide unique and valuable health solutions for patients and consumers alike, but also have the capacity to have a significant impact on the global healthcare market.

That's our target and "North-Star" for the Company and one which I hope you share with me and all of us who are working to make this a valuable reality for our shareholders.

Sincerely,

Craig Cooper
CEO & Managing Director

Approved by the Board of Directors and Released by Philip Leighfield, Company Secretary.

For more information please contact:

Investor Relations
Rod Hinchcliffe
rod.hinchcliffe@mcpartners.com.au

Media Relations
Melissa Hamilton
melissa.hamilton@mcpartners.com

About CardieX
CardieX is a global health technology company that focuses on hypertension, cardiovascular disease, and other vascular health disorders. CardieX is listed on the Australian Stock Exchange (ASX:CDX).

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
CardieX Limited	
ABN	**Quarter ended ("current quarter")**
81 113 252 234	31 March 2021

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (9 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	907	3,203
1.2	Payments for		
	(a) research and development	(471)	(1,472)
	(b) product manufacturing and operating costs	(277)	(521)
	(c) advertising and marketing	(27)	(90)
	(d) leased assets	(69)	(204)
	(e) staff costs	(970)	(2,953)
	(f) administration and corporate costs	(629)	(1,638)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	-	-
1.5	Interest and other costs of finance paid	(40)	(146)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	523
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(1,576)**	**(3,298)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(32)	(41)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	722
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(32)**	**681**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	3,313	6,304
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(166)	(338)
3.5	Proceeds from borrowings	-	14
3.6	Repayment of borrowings	-	(460)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**3,147**	**5,520**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	3,322	2,062
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,576)	(3,298)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(32)	681

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	3,147	5,520
4.5	Effect of movement in exchange rates on cash held	18	(86)
4.6	**Cash and cash equivalents at end of period**	**4,879**	**4,879**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	4,879	3,322
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**4,879**	**3,322**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	287
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	1,040	1,040
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	US$173	US$173
7.4	**Total financing facilities**	AU$1,040 + US$173	AU$1,040 + US$173

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Loan facilities mentioned above include US$173k loan under the Payroll Protection Plan (1% annual interest rate, funds would be used to cover payroll expenses and loan would be forgivable up to 60% of payroll costs for the eight week period).

On 25 March 2020, the Company entered into a $1,500,000 term loan facility, secured against future R&D refunds to be received by the Company and its wholly owned subsidiary AtCor Medical Pty Ltd. The facility is a prepayment of forecast R&D tax incentive claim for the years ended 30 June 2020 and 2021. The Facility attracts interest at 1.25% per calendar month. The Group repaid $460,000 in November 2020 and will remit further repayment on lodgement of its 2021 R&D Incentive post 1 July 2021. Please refer to the ASX Announcement dated 25 March 2020 for further details.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,576)
8.2	Cash and cash equivalents at quarter end (item 4.6)	4,879
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	4,879
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	3.10

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
Answer: N/A	

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 27 April 2021

Authorised by: The Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.